| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 25
| Issue : 7 | Page : 975-978 |
|
|
Ischemia-Modified Albumin (IMA) levels in ectopic pregnancy and early pregnancy loss
K Dogan1, C Helvacioglu1, S Baghaki1, A Kural2, M Dogan3
1 Department of Obstetrics and Gynecology, University of Health Sciences Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital, Istanbul, Turkey
2 Department of Biochemistry, University of Health Sciences Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital, Istanbul, Turkey
3 Department of Anesthesiology and Reanimation, University of Health Sciences Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital, Istanbul, Turkey
Correspondence Address:
Dr. K Dogan
Tevfik Saglam Street, No: 11, Zuhuratbaba, Bakirkoy, Istanbul
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/njcp.njcp_1464_21
|
|
|
Background: IMA is a novel marker to consider in ischemic conditions. The initial stages of pregnancy represent a physiological ischemic status. IMA levels may be changed when there is suspicion of early pregnancy complications because of increased oxidative stress. Aim: We aimed to determine and compare IMA values in cases of ectopic and healthy pregnancies as well as early pregnancy loss. Methods: This prospective case control study population (n = 91) consisted of early pregnancy loss (n = 28), ectopic pregnancy (n = 28), and an intracavitary early healthy pregnancy (n = 35). The serum IMA levels were compared in these groups. Results: Demographic parameters were similar and there was no significant difference between the three groups in terms of serum IMA concentrations. Conclusion: We suggested that IMA cannot be used clinically for the diagnosis and follow up of early pregnancy complications during the first five to six gestational weeks.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
